<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293394</url>
  </required_header>
  <id_info>
    <org_study_id>NP2743</org_study_id>
    <nct_id>NCT03293394</nct_id>
  </id_info>
  <brief_title>Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>tDCS_MND</acronym>
  <official_title>Rehabilitative Trial With Transcranial Direct Current Stimulation (tDCS) in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of
      neurological disorders that selectively affect motor neurons, the cells that control
      voluntary muscles of the body. The disorder causes muscle weakness and atrophy throughout the
      body due to the degeneration of the upper and lower motor neurons. Current drugs approved for
      ALS treatment only modestly slow disease progression.

      Transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been
      demonstrated to modulate cerebral excitability in several neurodegenerative disorders and
      modulate intracortical connectivity measures.

      In this randomized, double-blind, sham-controlled study, the investigators will evaluate
      whether a two-weeks' treatment with bilateral motor cortex anodal tDCS and spinal cathodal
      tDCS can improve symptoms in patients with amyotrophic lateral sclerosis and modulate
      intracortical connectivity, at short and long term.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of
      neurological disorders that selectively affect motor neurons, the cells that control
      voluntary muscles of the body. The disorder causes muscle weakness and atrophy throughout the
      body due to the degeneration of the upper and lower motor neurons. Current drugs approved for
      ALS treatment only modestly slow disease progression.

      Transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been
      demonstrated to modulate cerebral excitability in several neurodegenerative disorders and
      modulate intracortical connectivity measures.

      In this randomized, double-blind, sham-controlled study, the investigators will evaluate
      whether a two-weeks' treatment with bilateral motor cortex anodal tDCS and spinal cathodal
      tDCS can improve symptoms in patients with amyotrophic lateral sclerosis and modulate
      intracortical connectivity, at short and long term.

      Subjects will be randomized in two groups, one receiving a 10 day (5 days/week for 2 weeks)
      treatment with anodal bilateral motor cortex tDCS and cathodal spinal tDCS and the other
      receiving sham stimulation with identical parameters. After the intervention, patients will
      be reassessed with a clinical and neurophysiological evaluation at 2 weeks, 2 months and 6
      months after treatment. Furthermore, blood neurofilaments will be measured at each time
      point.

      Clinical evaluation will include the ALSFRS-R, ALSAQ-40, CBI, EQ-5D-5L, muscle strength
      evaluated with the MRC scale.

      Neurophysiological evaluation will include measures of intracortical connectivity, evaluated
      with transcranial magnetic stimulation (TMS) as short interval intracortical inhibition
      (SICI-ICF), long interval intracortical inhibition (LICI), short interval intracortical
      facilitation (SICF).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">October 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in short-interval intracortical inhibition-facilitation (SICI-ICF) from baseline</measure>
    <time_frame>Baseline - 2 weeks</time_frame>
    <description>By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of tDCS on short-interval intracortical inhibition-facilitation (SICI-ICF) from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in short-interval intracortical inhibition-facilitation (SICI-ICF) from baseline</measure>
    <time_frame>Baseline - 2 weeks - 2 months - 6 months</time_frame>
    <description>By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of tDCS on short-interval intracortical inhibition-facilitation (SICI-ICF) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in short-interval intracortical facilitation (SICF) from baseline</measure>
    <time_frame>Baseline - 2 weeks - 2 months - 6 months</time_frame>
    <description>By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of tDCS on short-interval intracortical facilitation (SICF) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in long-interval intracortical inhibition (LICI) from baseline</measure>
    <time_frame>Baseline - 2 weeks - 2 months - 6 months</time_frame>
    <description>By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of tDCS on long-interval intracortical inhibition (LICI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in the ALSFRS-R score from baseline</measure>
    <time_frame>Baseline - 2 weeks - 2 months - 6 months</time_frame>
    <description>Decline in the ALS Functional Rating Scale (ALSFRS-R) score from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline of muscle strength from baseline</measure>
    <time_frame>Baseline - 2 weeks - 2 months - 6 months</time_frame>
    <description>A megascore will be obtained by summing scores of single muscles manually evaluated according to the Medical Research Council (MRC) Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life from baseline</measure>
    <time_frame>Baseline - 2 weeks - 2 months - 6 months</time_frame>
    <description>Change of quality of life from baseline evaluated with the ALSAQ-40 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood neurofilaments</measure>
    <time_frame>Baseline - 2 weeks - 2 months - 6 months</time_frame>
    <description>Change of blood neurofilaments measures from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months - 24 months</time_frame>
    <description>Difference in survival between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Real tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days anodal bilateral motor cortex and cathodal spinal tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 days sham bilateral motor cortex and sham spinal tDCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anodal bilateral motor cortex and cathodal spinal tDCS</intervention_name>
    <description>10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)</description>
    <arm_group_label>Real tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham bilateral motor cortex and sham spinal tDCS</intervention_name>
    <description>10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)</description>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of probable, laboratory-supported probable, or definite
             amyotrophic lateral sclerosis according to the El Escorial revised criteria

          -  Disease duration ≤ 24 months

          -  Disease progression in the past 3 months

          -  Score ≥ 2 at the item &quot;swallowing&quot; of the ALS Functional Rating Scale Revised

          -  Score ≥ 2 at the item &quot;walking&quot; of the ALS Functional Rating Scale Revised

          -  Treatment with steady regimen of riluzole for a minimum of 1 month before study entry,
             and desiring its continuation

          -  Able to give informed consent

          -  Written informed consent

        Exclusion Criteria:

          -  Motor neuron diseases other than ALS

          -  Severe head trauma in the past

          -  History of seizures

          -  History of ischemic stroke or hemorrhage

          -  Pacemaker

          -  Metal implants in the head/neck region

          -  Severe comorbidity

          -  Intake of illegal drugs

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Borroni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Spedali Civili, Brescia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Borroni, MD</last_name>
    <phone>+39 030 3995631</phone>
    <email>barbara.borroni@unibs.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AO Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Borroni, MD</last_name>
      <phone>00390303995632</phone>
      <email>bborroni@inwind.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Quartarone A, Lang N, Rizzo V, Bagnato S, Morgante F, Sant'angelo A, Crupi D, Battaglia F, Messina C, Girlanda P. Motor cortex abnormalities in amyotrophic lateral sclerosis with transcranial direct-current stimulation. Muscle Nerve. 2007 May;35(5):620-4.</citation>
    <PMID>17221883</PMID>
  </reference>
  <reference>
    <citation>Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29. Review.</citation>
    <PMID>27866120</PMID>
  </reference>
  <reference>
    <citation>Menon P, Geevasinga N, Yiannikas C, Howells J, Kiernan MC, Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015 May;14(5):478-84. doi: 10.1016/S1474-4422(15)00014-9. Epub 2015 Apr 3. Erratum in: Lancet Neurol. 2015 Jun;14(6):566.</citation>
    <PMID>25843898</PMID>
  </reference>
  <reference>
    <citation>Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011 Sep;134(Pt 9):2582-94. doi: 10.1093/brain/awr195. Epub 2011 Aug 11.</citation>
    <PMID>21840887</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Barbara Borroni</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

